← Back to all trials
Not Yet Recruiting
NCT07758127
Updates and Insights on HER2 in Breast Cancer in Sohag Governorate
Conditions: HER2 Status in Breast Cancer
Sex: Female
Ages: 26 Years – 85 Years
Healthy volunteers: No
Enrollment: 100
Sponsor: Sohag University
Location: Faculty of medicine sohag university Sohag
Summary
* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.
* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes
* To access interobserval agreement in HER2 score interpretation
Eligibility Criteria
Inclusion Criteria:
* 1\) Breast cancer cases diagnosed during 2025 and 2026. 2) Cases with available HER2 immunohistochemical results. 3) Cases with sufficient tissue material for evaluation. 4) Cases with complete clinical and follow-up data. 5) Cases that were accessible for pathologic review
Exclusion Criteria:
1. Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.
2. Cases with incomplete clinical information.
3. Cases lacking adequate immunohistochemical assessment.
4. Cases outside the study period
Source: ClinicalTrials.gov (NCT07758127). StuddyBuddy aggregates publicly available trial information.
